Candriam SCA’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Candriam SCA’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-490,585	Closed	-$36.9M	–	902
2022 Q2	$36.9M	Sell	490,585 -12,703	-3%	-$565K	0.3%	83
2022 Q1	$13.5M	Sell	503,288 -72,200	-13%	-$2.43M	0.09%	210
2021 Q4	$27.5M	Buy	575,488 +54,863	+11%	+$2.45M	0.18%	138
2021 Q3	$34.6M	Hold	520,625	–	–	0.24%	101
2021 Q2	$40.6M	Buy	520,625 +63,684	+14%	+$4.71M	0.28%	82
2021 Q1	$53.5M	Sell	456,941 -5	-0%	-$595	0.45%	50
2020 Q4	$55.7M	Buy	456,946 +221,783	+94%	+$24.3M	0.44%	50
2020 Q3	$20.5M	Sell	235,163 -2,918	-1%	-$203K	0.19%	132
2020 Q2	$15.4M	Buy	238,081 +85,441	+56%	+$4.93M	0.16%	155
2020 Q1	$9.29M	Buy	152,640 +12	+0%	+$637	0.1%	225
2019 Q4	$9.51M	Buy	152,628 +119,628	+363%	+$5.69M	0.1%	227
2019 Q3	$1.24M	Buy	+33,000	New	+$1.44M	0.02%	570

Candriam SCA's TPTX Position: Q3 2022 in Review

Candriam SCA sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 490,585 shares — an estimated $36.9M sold.

Candriam SCA first reported a position in TPTX in Q3 2019 and held it in 12 quarters. The position peaked at $55.7M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Candriam SCA reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Candriam SCA sold 490,585 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $36.9M.
Candriam SCA first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 12 quarters.
Candriam SCA's Turning Point Therapeutics, Inc. Common Stock position peaked at $55.7M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.